Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
74.45
-1.80 (-2.36%)
Apr 28, 2026, 3:00 PM CST
147.51%
Market Cap 46.02B
Revenue (ttm) 4.32B
Net Income (ttm) 2.97B
Shares Out 618.09M
EPS (ttm) 4.78
PE Ratio 15.56
Forward PE 71.59
Dividend 0.48 (0.63%)
Ex-Dividend Date Nov 7, 2025
Volume 8,996,583
Average Volume 11,969,508
Open 77.40
Previous Close 76.25
Day's Range 74.25 - 78.24
52-Week Range 26.80 - 96.60
Beta 0.55
RSI 43.44
Earnings Date Mar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,012
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.90 billion, an increase of 311.49%.

Financial Statements

News

There is no news available yet.